RxDoctor Payments Data

Jacquelyn Lamigo

Optometrist · Anchorage, AKNPI 1568956563

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.4% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Alcon at 33.4% of the total.

$1,222in general payments, 2019–2025

Across 31 payments — averaging $39.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$409
  • Bausch & Lomb Americas Inc.$212
  • AbbVie$172
  • Mallinckrodt Hospital Products Inc.$144
  • Sun Pharmaceutical Industries Inc.$101
  • Johnson & Johnson Vision Care, Inc.$57
  • plus $127 from 5 others

What the payments were for

  • Food & beverage$1,20398%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,222 in reported general payments places this provider in the 70th percentile of 163 optometrist providers in Alaska.

See all optometrist providers in Alaska

Medicare billing

Part B allowed, 2024
$124,653
Medicare patients
535
Services billed
1,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine44$38,451
LumiganBimatoprost45$28,826
RestasisCyclosporine15$20,169
Travoprost11$2,455
Timolol Maleate57$2,354
Latanoprost39$740
Prednisolone Acetate18$576
Doxycycline Hyclate17$333
ErythromycinErythromycin Base15$238
MoxifloxacinMoxifloxacin Hcl11$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$172$48,99560 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 163 optometrist providers in Alaska.

Other optometrist in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →